Status and phase
Conditions
Treatments
About
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder. The secondary objectives are to evaluate the efficacy of saredutant on disability and quality of life in patients with generalized anxiety disorder, and to evaluate blood levels of saredutant.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
The investigator will evaluate whether there are other reasons why a patient may not participate.
Primary purpose
Allocation
Interventional model
Masking
365 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal